Prospera Financial Services Inc Cellectar Biosciences, Inc. Transaction History

Prospera Financial Services Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 08, 2022	SELL	$3.5 - $6.9 $29,750 - $58,650	-8,500 Reduced 61.8%	5,254 $2,000
Q4 2021 Feb 10, 2022	SELL	$6.1 - $10.2 $6,100 - $10,200	-1,000 Reduced 6.78%	13,754 $9,000
Q1 2021 May 06, 2021	BUY	$15.2 - $25.0 $224,260 - $368,850	14,754 New	14,754 $24,000
Q4 2020 Feb 12, 2021	SELL	$11.2 - $27.7 $11,200 - $27,700	-1,000 Closed	0 $0
Q3 2020 Nov 04, 2020	BUY	$10.6 - $16.6 $10,600 - $16,600	1,000 New	1,000 $1,000

Ticker CLRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,114,290
Market Cap $13M
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...

Get notified when there are updates to the investment portfolio of Prospera Financial Services Inc, based on Form 13F filings with the SEC.

Stay updated on Prospera Financial Services Inc with notifications on news.